Addex Therapeutics Ltd. (ADXN)
Stock Price:
$9.16 USD
0.00 (0.00%)
Updated Jul 8, 2020 4:00 PM EDT - Market open
Key Info
| Market Cap |
300.89M |
| Revenue (ttm) |
2.85M |
| Net Income (ttm) |
-15.24M |
| Shares Out |
27.00M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$9.16 |
| Previous Close |
$9.16 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
9.16 - 9.16 |
| Day's Volume |
0 |
| 52-Week Range |
6.19 - 14.50 |
More Stats
| Market Cap |
300.89M |
| Enterprise Value |
268.93M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.00M |
| Float |
3.12M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.79 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
570 |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
105.64 |
| PB Ratio |
11.79 |
| Revenue |
2.85M |
| Operating Income |
-15.13M |
| Net Income |
-15.24M |
| Free Cash Flow |
-9.80M |
| Net Cash |
31.96M |
| Net Cash / Share |
0.97 |
| Gross Margin |
100.00% |
| Operating Margin |
-531.16% |
| Profit Margin |
-535.00% |
| FCF Margin |
-344.23% |
| ROA |
-17.16% |
| ROE |
-52.59% |
| ROIC |
538.10% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions CHF.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 2.76 | 6.04 | - |
| Revenue Growth | -54.29% | - | - |
| Gross Profit | 2.76 | 6.04 | - |
| Operating Income | -14.67 | -2.08 | -3.73 |
| Net Income | -14.78 | -1.64 | -3.28 |
| Shares Outstanding | 32.85 | 32.85 | - |
| Earnings Per Share | -0.56 | -0.07 | -0.25 |
| Operating Cash Flow | -9.48 | 1.75 | -2.14 |
| Capital Expenditures | -0.03 | -0.01 | - |
| Free Cash Flow | -9.51 | 1.74 | -2.14 |
| Cash & Equivalents | 31.55 | 41.68 | 2.59 |
| Total Debt | 0.55 | - | - |
| Net Cash / Debt | 31.00 | 41.68 | 2.59 |
| Assets | 33.03 | 42.21 | 3.06 |
| Liabilities | 7.50 | 2.97 | 1.72 |
| Book Value | 25.52 | 39.24 | 1.34 |
Numbers in millions CHF, except per-share numbers.
Company Details
| Full Name |
Addex Therapeutics Ltd. |
| Country |
Switzerland |
| Employees |
19 |
| CEO |
Timothy Dyer |
Stock Information
| Ticker Symbol |
ADXN |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: ADXN |
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.